Anchiano Therapeutics (NASDAQ:ANCN) and ContraFect (NASDAQ:CFRX) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their analyst recommendations, dividends, institutional ownership, profitability, risk, valuation and earnings.
This table compares Anchiano Therapeutics and ContraFect’s net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
Risk and Volatility
Anchiano Therapeutics has a beta of 0.75, meaning that its stock price is 25% less volatile than the S&P 500. Comparatively, ContraFect has a beta of 1, meaning that its stock price has a similar volatility profile to the S&P 500.
This is a breakdown of recent recommendations and price targets for Anchiano Therapeutics and ContraFect, as provided by MarketBeat.com.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
Anchiano Therapeutics presently has a consensus price target of $16.00, indicating a potential upside of 1,169.84%. ContraFect has a consensus price target of $16.00, indicating a potential upside of 186.23%. Given Anchiano Therapeutics’ higher probable upside, equities analysts plainly believe Anchiano Therapeutics is more favorable than ContraFect.
Valuation and Earnings
This table compares Anchiano Therapeutics and ContraFect’s gross revenue, earnings per share (EPS) and valuation.
|Gross Revenue||Price/Sales Ratio||Net Income||Earnings Per Share||Price/Earnings Ratio|
|Anchiano Therapeutics||N/A||N/A||-$27.12 million||($3.46)||-0.36|
Anchiano Therapeutics is trading at a lower price-to-earnings ratio than ContraFect, indicating that it is currently the more affordable of the two stocks.
Insider and Institutional Ownership
12.7% of Anchiano Therapeutics shares are owned by institutional investors. Comparatively, 55.3% of ContraFect shares are owned by institutional investors. 6.9% of Anchiano Therapeutics shares are owned by company insiders. Comparatively, 3.7% of ContraFect shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.
ContraFect beats Anchiano Therapeutics on 7 of the 11 factors compared between the two stocks.
About Anchiano Therapeutics
Anchiano Therapeutics Ltd, a clinical-stage biotechnology company, develops gene therapies to treat early-stage bladder cancer. It is primarily developing Inodiftagene that is in various clinical trials for the treatment of non-muscle-invasive bladder cancer. The company was formerly known as BioCancell Ltd. and changed its name Anchiano Therapeutics Ltd in July 2018. The company was founded in 2004 and is headquartered in Cambridge, Massachusetts.
ContraFect Corporation, a clinical-stage biotechnology company, focuses on the discovery and development of therapeutic protein and antibody products for the treatment of life-threatening and drug-resistant infectious diseases in the United States. Its lead product candidates consist of CF-301, a lysin, which has completed Phase II clinical trials for the treatment of staphylococcus aureus bacteremia, including endocarditis caused by methicillin-resistant or methicillin-susceptible; and CF-404, a combination of monoclonal antibodies (mAbs), which is in preclinical trial stage for the treatment of life-threatening seasonal and pandemic influenza infections. The company has a collaboration research agreement with The Rockefeller University to identify new lysin therapeutic candidates targeting gram-negative pathogens; and license agreement with Trellis Bioscience LLC for mAbs in the field of influenza. ContraFect Corporation was founded in 2008 and is headquartered in Yonkers, New York.
Receive News & Ratings for Anchiano Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Anchiano Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.